^
    2years
    SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity. (PubMed, Sci Rep)
    Treatment with PEN-221 rapidly reduced the abundance of CAR T cells, decreasing the severity of xenogeneic graft-versus-host disease (GvHD), and prolonged survival. Our study supports the development of SSTR2 as a single genetic marker for CAR T cells that is readily applicable to humans both for anatomical detection of T cell distribution and an image-guided safety switch for rapid elimination of CAR T cells.
    Journal • CAR T-Cell Therapy
    |
    SSTR (Somatostatin Receptor) • ICAM1 (Intercellular adhesion molecule 1) • SSTR2 (Somatostatin Receptor 2)
    |
    nendratareotide uzatansine (PEN-221)
    3years
    [VIRTUAL] The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 Results (NANETS 2021)
    PEN-221 appears well tolerated at 8.8 mg/m2 q 3 weeks and has demonstrated efficacy exceeding its clinical efficacy goals with a CBR of 88.5% and a mPFS of 9 months.
    Clinical • P2 data
    |
    ALK (Anaplastic lymphoma kinase) • SSTR2 (Somatostatin Receptor 2)
    |
    nendratareotide uzatansine (PEN-221)
    almost4years
    PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers (clinicaltrials.gov)
    P1/2, N=89, Completed, Tarveda Therapeutics | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    SSTR positive • SSTR2 positive
    |
    nendratareotide uzatansine (PEN-221)
    over4years
    Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer. (PubMed, Mol Cancer Ther)
    The unique attributes of the miniaturized drug conjugate allowed for deep tumor penetration and limited plasma exposure that may enable long-term dosing, resulting in durable tumor control. Collectively, these data suggest potential for antitumor activity of PEN-221 in patients with SSTR2-positive SCLC.
    Journal
    |
    CASP3 (Caspase 3)
    |
    nendratareotide uzatansine (PEN-221)